Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar;1(1):e1-e9.
doi: 10.1016/j.scog.2014.02.001.

Cognition in schizophrenia: Past, present, and future

Michael F Green  1 , Philip D Harvey  2
Affiliations

Cognition in schizophrenia: Past, present, and future

Michael F Green et al. Schizophr Res Cogn. 2014 Mar.

Abstract

Schizophrenia Research: Cognition will serve an important function - a place where interests converge and investigators can learn about the recent developments in this area. This new journal will provide rapid dissemination of information to people who will make good use of it. In this initial article, we comment globally on the study of cognition in schizophrenia: how we got here, where we are, and where we are going. The goal of this first article is to place the study of cognition in schizophrenia within a historical and scientific context. In a field as richly textured as ours it is impossible to hit all the important areas, and we hope the reader will forgive our omissions. Phrased in cognitive terms, our limited presentation of the past is a matter of selective memory, the present is a matter of selective attention, and the future is a matter of selective prospection. This broad introduction emphasizes that cognition in schizophrenia provides clues to pathophysiology, treatment, and outcome. In fact, the study of cognitive impairment in schizophrenia has become wholly intertwined with the study of schizophrenia itself.

Keywords: Cognition; History; Schizophrenia.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

Dr. Green has been a consultant to AbbVie, Biogen, DSP, and Roche, and he is on the scientific advisory board of Mnemosyne. He has received research funds from Amgen. Dr. Harvey has received a contract research grant from Genentech, and has received honoraria for consulting or travel support from AbbVie, Boeheringer Ingelheim, En Vivo, Genentech, Otsuka America, Roche, Sunovion, Shire, and Takeda.

References

    1. Andreasen NC, Olsen SA. Negative vs. positive schizophrenia: Definition and validation. Arch. Gen. Psychiatry. 1982;39:789–794. - PubMed
    1. Andreasen NC, Rezai K, Alliger R, Swayze VW, Flaum M, Kirchner P, Cohen G, O’Leary DS. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Arch. Gen. Psychiatry. 1992;49:943–958. - PubMed
    1. Anticevic A, Van Snellenberg JX, Cohen RE, Repovs G, Dowd EC, Barch DM. Amygdala recruitment in schizophrenia in response to aversive emotional material: a meta-analysis of neuroimaging studies. Schizophr. Bull. 2012;38(3):608–621. - PMC - PubMed
    1. Barch DM, Bustillo J, Gaebel W, Gur R, Heckers S, Malaspina D, Owen MJ, Schultz S, Tandon R, Tsuang M, Van Os J, Carpenter W. Logic and justification for dimensional assessment of symptoms and related clinical phenomena in psychosis: relevance to DSM-5. Schizophr. Res. 2013;150(1):15–20. - PubMed
    1. Beck AT, Rector NA, Stolar N, Grant P. Schizophrenia: cognitive theory, research, and therapy. New York, NY: Guilford Press; 2009.